Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Genomics & Proteomics
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Cancer Genomics & Proteomics

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Review ArticleR
Open Access

The Translational Potential for Target Validation and Therapy Using Intracellular Antibodies in Oncology

ULRICH H. WEIDLE, DANIELA MAISEL, ULRICH BRINKMANN and GEORG TIEFENTHALER
Cancer Genomics & Proteomics November 2013, 10 (6) 239-250;
ULRICH H. WEIDLE
Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANIELA MAISEL
Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ULRICH BRINKMANN
Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORG TIEFENTHALER
Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Antibody-based molecules can be delivered into cells either by intracellular expression or through cellular uptake. We describe technologies for identification and expression of intracellular antibodies for target validation, intracellular immunization and tumor therapy, such as intracellular antibody capture technology, suicide or silencing technology, antigen-antibody interaction dependent apoptosis and their application for inhibition of oncogenic intracellular proteins and induction of apoptosis. These strategies have to be viewed in the context that inhibition of protein-protein interactions by small molecules is often limited due to their large interaction surface. We summarize antibodies with the ability to penetrate cells and strategies to induce uptake of antibodies after modification with protein transduction domains. Interference in oncogenic pathways is described for moieties based on antibody 3E10, which translocates into the nucleus after extracellular administration. Finally, we discuss examples of tumor immunotherapy and vaccination against intracellular antigens, and possible interactions mediating their mode of action.

  • Autoimmune disease-related antibodies
  • cancer immunotherapy against intracellular targets
  • intracellular immunization
  • inhibition of oncogenic pathways
  • mechanisms of antibody uptake
  • protein knock-down
  • target validation
  • protein transduction domain
  • review
  • Received October 8, 2013.
  • Revision received November 7, 2013.
  • Accepted November 8, 2013.
  • Copyright © 2013 The Author(s). Published by the International Institute of Anticancer Research.

View Full Text
PreviousNext
Back to top

In this issue

Cancer Genomics & Proteomics
Vol. 10, Issue 6
November-December 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cancer Genomics & Proteomics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Translational Potential for Target Validation and Therapy Using Intracellular Antibodies in Oncology
(Your Name) has sent you a message from Cancer Genomics & Proteomics
(Your Name) thought you would like to see the Cancer Genomics & Proteomics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Translational Potential for Target Validation and Therapy Using Intracellular Antibodies in Oncology
ULRICH H. WEIDLE, DANIELA MAISEL, ULRICH BRINKMANN, GEORG TIEFENTHALER
Cancer Genomics & Proteomics Nov 2013, 10 (6) 239-250;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The Translational Potential for Target Validation and Therapy Using Intracellular Antibodies in Oncology
ULRICH H. WEIDLE, DANIELA MAISEL, ULRICH BRINKMANN, GEORG TIEFENTHALER
Cancer Genomics & Proteomics Nov 2013, 10 (6) 239-250;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Systems for Intracellular Expression of Antibodies
    • Intracellular Monoclonal Antibodies (mAbs) Directed Against Oncogenic Kinases
    • Cell-penetrating Antibodies
    • Cellular Uptake of Modified Antibodies
    • Antibody 3E10-based Internalizing Moieties
    • mAb-based Immunotherapy Against Intracellular Targets
    • Conclusion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus
  • Google Scholar

Keywords

  • Autoimmune disease-related antibodies
  • cancer immunotherapy against intracellular targets
  • intracellular immunization
  • inhibition of oncogenic pathways
  • mechanisms of antibody uptake
  • protein knock-down
  • target validation
  • protein transduction domain
  • review
Cancer & Genome Proteomics

© 2026 Cancer Genomics & Proteomics

Powered by HighWire